Dallas TX 非霍奇金淋巴瘤临床试验
17项针对 非霍奇金淋巴瘤的研究正在 Dallas及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本(英文)
正在为研究招募参与者?将此页面置顶展示 — $99 / 30天 →
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
招募中2 期
- UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730), Dallas
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
招募中1/2 期
- Baylor Scott & White Research Institute, Texas Oncology, Dallas
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
招募中1 期
- University of Texas Southwestern, Dallas
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
招募中1 期
- Texas Oncology - DFW (Sammons CC), Dallas
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
招募中1 期
- Baylor University Medical Center, Dallas
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
招募中1/2 期
- Baylor University Medical Center, Dallas
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
招募中观察性研究
- UT Southwestern Medical Center, Dallas
DALY II USA/ MB-CART2019.1 for DLBCL
招募中2 期
- UT Southwestern Medical Center, Dallas
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
招募中观察性研究
- Medical City Dallas, Dallas
- Children's Medical Center Dallas, Dallas
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
招募中1/2 期
- University of Texas Southwestern Medical Center, Dallas
Study of SGR-1505 in Mature B-Cell Neoplasms
招募中1 期
- University of Texas Southwestern, Dallas
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
招募中1 期
- UT Southwestern Medical Center, Dallas
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
招募中观察性研究
- Ut Southwestern, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Dallas
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
招募中观察性研究
- University of Texas Southwestern, Dallas
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
招募中1 期
- University of Texas Southwestern Medical Center, Dallas
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
招募中1/2 期
- UT Southwestern Medical Center, Dallas
其他城市的 非霍奇金淋巴瘤试验
- Houston, TX31 项研究
- New York City, NY31 项研究
- Boston, MA26 项研究
- Nashville, TN21 项研究
- Philadelphia, PA20 项研究
- Baldwin Park, CA19 项研究
- Washington, DC18 项研究
- Atlanta, GA18 项研究
- Chicago, IL18 项研究
- Milwaukee, WI18 项研究
- Columbus, OH18 项研究
- Seattle, WA16 项研究
Dallas的其他研究
- 乳腺癌55 项研究
- 非小细胞肺癌52 项研究
- 转移性癌症42 项研究
- 心力衰竭42 项研究
- 癌症(所有类型)37 项研究
- 前列腺癌36 项研究
- 结直肠癌33 项研究
- 肥胖症30 项研究
- 卵巢癌28 项研究
- 肺癌27 项研究
- 膀胱癌27 项研究
- 子宫内膜癌24 项研究
数据来自 ClinicalTrials.gov,检索日期:2026年10月6日。每项研究自行设定入选标准,由研究团队决定谁能参与。